Abstract
Elevated concentrations of interleukin-18 (IL-18) are found in both serum and synovial fluid of patients suffering from rheumatoid arthritis (RA) and this cytokine has recently been implicated in the development of experimental arthritis. In this present study, we developed an IL-18 neutralizing intervention and examined its efficacy for local intra-articular treatment of experimental arthritis. To this end we constructed an adenoviral vector containing the murine IL-18 binding protein isoform c gene (AdCMVIL-18BPc). The constructed adenoviral vector was validated on replication deficiency, transfection efficacy and ability to express biological functional IL-18BPc. Intra-articular overexpression of IL-18BPc significantly reduced incidence of collagen-induced arthritis (CIA) in treated kneejoints. Affected kneejoints of IL-18BPc-treated mice showed less severe arthritis, characterized by reduction of inflammation and destruction of bone and cartilage. Local intra-articular IL-1BPc treatment in both knees provided additional protection against CIA incidence and severity in distal paws. Measurement of serum levels of specific collagen type (CII) Abs revealed a moderate reduction of circulating IgG2a anti-CII Abs, while IgG1 anti-CII Abs remained at similar level. The present study underlines the involvement of IL-18 as an important proinflammatory cytokine in onset of experimental arthritis. Furthermore, it shows that endogenous IL-18 can be blocked efficiently through local adenoviral overexpression of IL-18BPc, indicating that treatment with IL-18BPc might contribute to joint protection in RA.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nakamura K et al. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 1989; 57: 590–595.
Akira S . The role of IL-18 in innate immunity. Curr Opin Immunol 2000; 12: 59–63.
Kohno K et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158: 1541–1550.
Okamura H et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88–91.
Puren AJ et al. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998; 101: 711–721.
Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H . Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001; 12: 53–72.
Stoll S et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 1998; 28: 3231–3239.
Stoll S et al. Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 1997; 159: 298–302.
Udagawa N et al. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 1997; 185: 1005–1012.
Torigoe K et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997; 272: 25737–25742.
Born TL, Thomassen E, Bird TA, Sims JE . Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998; 273: 29445–29450.
Novick D et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999; 10: 127–136.
Paulukat J et al. Expression and release of IL-18 binding protein in response to IFN- gamma. J Immunol 2001; 167: 7038–7043.
Kim SH et al. Structural requirements of six naturally occurring isoforms of the IL- 18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 2000; 97: 1190–1195.
Xiang Y, Moss B . IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. Proc Natl Acad Sci USA 1999; 96: 11537–11542.
Joosten LAB et al. Association of interleukin-18 expression with enhanced levels of both interleukin-1β and Tumor Necrosis Factor α in Knee Synovial Tissue of patients with Rheumatoid Arthritis. Arthritis & Rheum 2003; 48: 339–347.
Bresnihan B et al. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis 2002; 61: 726–729.
Gracie JA et al. A proinflammatory role for IL-18 in rheumatoid arthritis [see comments]. J Clin Invest 1999; 104: 1393–1401.
Yamamura M et al. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 2001; 44: 275–285.
Pittoni V et al. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 2002; 61: 723–725.
Wei X et al. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001; 166: 517–521.
Joosten LAB et al. An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol 2000; 165: 6553–6558.
Plater-Zyberk C et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001; 108: 1825–1832.
Okamura H et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70: 281–312.
Bakker AC et al. A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Therapy 2001; 8: 1785–1793.
Bakker AC et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893–900.
Dinarello CA . Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw 2000; 11: 483–486.
Dinarello CA et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol 1998; 63: 658–664.
Micallef MJ et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996; 26: 1647–1651.
Okamura H et al. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 1998; 10: 259–264.
Leung BP et al. Combined effects of IL-12 and IL-18 on the induction of collagen- induced arthritis. J Immunol 2000; 164: 6495–6502.
Roth S et al. Anti-TNF alpha monoclonal antibodies (infliximab) and tuberculosis: apropos of 3 cases. Rev Med Interne 2002; 23: 312–316.
Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E . Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol 2002; 31: 44–45.
Sicotte NL, Voskuhl RR . Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57: 1885–1888.
He TC et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509–2514.
van den Broek MF, van Den Berg WB, van de Putte LB, Severijnen AJ . Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol 1988; 133: 139–149.
van de Loo FAJ et al. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice. Am J Pathol 1997; 151: 177–191.
Drenth JP et al. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J Appl Physiol 1995; 79: 1497–1503.
Acknowledgements
We thank Inneke Verschueren (Department of Internal Medicine, University Medical Center Nijmegen) for determination of TNFα levels in provided samples.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smeets, R., van de Loo, F., Arntz, O. et al. Adenoviral delivery of IL-18 binding protein C ameliorates Collagen-Induced Arthritis in mice. Gene Ther 10, 1004–1011 (2003). https://doi.org/10.1038/sj.gt.3301986
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301986
Keywords
This article is cited by
-
IL-18 binding protein suppresses IL-17-induced osteoclastogenesis and rectifies type 17 helper T cell / regulatory T cell imbalance in rheumatoid arthritis
Journal of Translational Medicine (2021)
-
Dual role of shikonin in early and late stages of collagen type II arthritis
Molecular Biology Reports (2009)
-
Therapeutic effect of low-dose IL-18 combined with IL-10 on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of Th2 responses
Rheumatology International (2009)
-
Transgene Persistence and Cell Turnover in the Diarthrodial Joint: Implications for Gene Therapy of Chronic Joint Diseases
Molecular Therapy (2007)
-
Gentherapie zur Behandlung der akuten inflammatorischen Immunantwort
Der Orthopäde (2007)